Assembly Biosciences (ASMB) Cash & Equivalents (2010 - 2026)

Assembly Biosciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $31.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 32.92% year-over-year to $31.1 million; the TTM figure through Mar 2026 stood at $31.1 million (up 32.92% YoY), while the FY2025 annual figure was $58.4 million, up 52.44% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $31.1 million, down from $58.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $58.4 million in Q4 2025, with the low at $18.1 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $28.5 million (2024), against an average of $33.9 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 62.15% in 2023, then soared 93.26% in 2024.
• Assembly Biosciences' Cash & Equivalents stood at $52.4 million in 2022, then slumped by 62.15% to $19.8 million in 2023, then jumped by 93.26% to $38.3 million in 2024, then surged by 52.44% to $58.4 million in 2025, then slumped by 46.76% to $31.1 million in 2026.
• Business Quant data shows ASMB's Cash & Equivalents at $31.1 million in Q1 2026, $58.4 million in Q4 2025, and $22.5 million in Q3 2025.